AliveCor Collaborates with European Market Leader in Remote Patient Monitoring Luscii to Offer World’s First ‘Virtual Heart Clinic in a Box’

AliveCor, the global leader in personal electrocardiogram (ECG) technology, has announced a groundbreaking collaboration with Luscii, Europe’s market leader in remote patient monitoring and virtual ward provider. Together, the companies will launch the world’s first ‘virtual heart clinic in a box’, revolutionising cardiac care for millions of patients by making it easy for any hospital or GP to deliver high-quality, remote patient monitoring to their patients.

Luscii Virtual Heart Clinic® aims to provide cardiologists with a comprehensive, easy-to-use app to offer remote cardiac patient monitoring to their patients. The app prompts patients to take measurements of vital signs which are automatically analysed to detect abnormalities. This results in an improved patient experience and more time to care for the clinical teams. Luscii therefore integrates AliveCor’s advanced 6-lead ECG technology next to Omron blood pressure meters and scale and Happitech PPG in its medically certified telehealth platform that is launched in 11 countries for over 100 conditions.

“We are excited to partner with Luscii utilising AliveCor’s SDK solution, bringing the possibilities of AliveCor to Luscii’s extensive network of renowned hospitals and GP’s in Europe and Africa”, said Chris Shelford, international marketing director at AliveCor. “Luscii’s Virtual Heart Clinic, in partnership with AliveCor, will further drive the transformation of cardiac care delivery, making it more accessible and convenient for patients while reducing the burden on healthcare systems.”

Luscii’s new offering will enable healthcare providers to monitor cardiac patients remotely, reducing the need for in-person visits or admissions and ensuring that patients receive the care they need. The use of the Luscii app in cardiac care already showed impressive results across Europe, such as 81% fewer unplanned admissions in heart failure patients in London (source) and 56% fewer in-person visits for AF in Amsterdam (source). This partnership will complement these possibilities by giving heart patients more control over their own health whilst staying connected with their care team.

“AliveCor’s cutting-edge ECG technology complements our widely used remote patient monitoring and virtual ward service, and we are proud to join forces” said Luscii co-founder Dr. Joris Janssen. “Now, we can help even more patients receiving care at home and support doctors and nurses to make cardiac care more accessible, efficient, and patient-centered.”

The Luscii AliveCor SDK implementation will become available to all Luscii customers immediately with the first hospitals expected to start offering Luscii Virtual Heart Clinic with AliveCor to their patients this summer in the Netherlands, Ireland and in the UK.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”